ACTH(4–10) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
=== Aerial capabilities === The Houthis exert partial control over the Yemeni Air Force, and possess key air bases such as Al-Dailami and Al Hudaydah. The Houthi air force consists of a single Northrop F-5 fighter jet, which was seized from the Yemeni government. The group also flew a Soviet-era Mikoyan MiG-29 during a military parade over Sanaa in 2023. They also operate Mil Mi-17 helicopters seized during the civil war.
=== The Healing Foundation === In 1998, as Treasurer of the British Association of Plastic, Reconstructive, and Aesthetic Surgeons (BAPRAS), Brough and his fellow Trustees established The Healing Foundation. Building on the groundwork laid by the Phoenix Appeal, The Healing Foundation aimed to advance research into surgical and psychological healing techniques for individuals with disfiguring conditions. Various UK medical membership bodies provided support to The Healing Foundation as Partner Member Organisations. These partnerships bolstered the charity's credibility, networking capabilities, and financial resources.These organisations were BAPRAS, the British Association of Aesthetic Surgeons, the British Psychological Society, the Craniofacial Society of Great Britain and Ireland, the British Burns Association, and the British Society for Surgery of the Hand.
However, a 2021 study on the decay chains of flerovium isotopes suggests that there is no strong stabilizing effect from Z = 114 in the region of known nuclei (N = 174), and that extra stability would be predominantly a consequence of the neutron shell closure. Although known nuclei still fall several neutrons short of N = 184 where maximum stability is expected (the most neutron-rich confirmed nuclei, 293Lv and 294Ts, only reach N = 177), and the exact location of the center of the island remains unknown, the trend of increasing stability closer to N = 184 has been demonstrated. For example, the isotope 285Cn, with eight more neutrons than 277Cn, has a half-life almost five orders of magnitude longer. This trend is expected to continue into unknown heavier isotopes in the vicinity of the shell closure.
These multidisciplinary teams leverage the Barshop Institute's nationally recognized aging research programs—including the Nathan Shock Center of Excellence in the Basic Biology of Aging, the Claude D. Pepper Older Americans Independence Center, the Center for Alzheimer's Disease and Related Dementias Population Aging and Social Studies (CAPAS), and the Interventions Testing Program—to rapidly translate mechanistic discoveries into human studies. This integrated research environment enables investigators to evaluate interventions targeting the fundamental biological mechanisms of aging rather than focusing solely on individual diseases, reflecting the principles of geroscience that underpin the Institute's research mission. A landmark addition to the Institute's clinical research portfolio is the Validation and Intervention Testing for Aging, Longevity and Healthspan (VITAL-H) clinical trial, supported by a contract of up to $38 million from the Advanced Research Projects Agency for Health (ARPA-H) through its Proactive Solutions for Prolonging Resilience (PROSPR) program. As the coordinating center for this first-of-its-kind national healthspan clinical trial, the Barshop Institute is leading an unprecedented effort to determine whether FDA-approved medications can slow the biological processes of aging and preserve health and functional capacity before the onset of chronic disease.
== Electrospray ionization == Electrospray ionization (ESI) is a technique that involves using high voltages to create an electrospray, or a fine aerosol created by the high voltages. ESI sample preparation can be very important and the quality of results can be heavily determined by the characteristics of the sample. ESI experiments can be run on-line or off-line. In on-line measurements the mass spectrometer is connected to a liquid chromatograph and as the samples are separated they are ionized into the mass spectrometer by the ESI system; sample preparation is actually performed before the LC separation. In off-line measurements, the analyte solution is applied directly to the mass spectrometer by a spray capillary . Off-line sample preparation has many considerations, such as the fact that the capillary used allows for the application of volumes in the nanoliter range, which can contain a concentration too small for analysis of many compounds, such as proteins. An additional problem can be loss of ESI signal due to interference between the analyte sample and background components. Unfortunately, it has been shown that sample preparation itself can only slightly alleviate this problem which is due more to the nature of the analyte itself than the preparation. In ESI the principal problem comes not from reactions in the gas phase but rather from problems involving the solution phase of the droplets themselves.
Sources: en.wikipedia.org
==== General consensus on use ==== There is consensus amongst stroke specialists that tPA is the standard of care for eligible stroke patients, and benefits outweigh the risks. There is significant debate mainly in the emergency medicine community regarding recombinant tPA's effectiveness in ischemic stroke. The NNT Group on evidence-based medicine concluded that it was inappropriate to combine these twelve trials into a single analysis, because of substantial clinical heterogeneity (i.e., variations in study design, setting, and population characteristics). Examining each study individually, the NNT group noted that two of these studies showed benefit to patients given tPA (and that, using analytical methods that they think flawed); four studies showed harm and had to be stopped before completion; and the remaining studies showed neither benefit nor harm. On the basis of this evidence, the NNT Group recommended against the use of tPA in acute ischaemic stroke. The NNT Group notes that the case for the 3-hour time window arises largely from analysis of two trials: NINDS-2 and subgroup results from IST-3. "However, presuming that early (0-3h) administration is better than later administration (3-4.5h or 4.5-6h) the subgroup results of IST-3 suggest an implausible biological effect in which early administration is beneficial, 3-4.5h administration is harmful, and 4.5-6h administration is again beneficial." Indeed, even the original publication of the IST-3 trial found that time-window effects were not significant predictors of outcome (p=0.61).
==== Education ==== Even with the acceleration of the transmission of COVID-19 in the city and the increase in the occupation of beds at hospitals, Melo maintained the plan to recommence classes in municipal schools on 22 February 2021. He had only cancelled the beginning of the school year when the city had been put under the black flag category, the highest category for social distancing, due to a high risk of infections. A part of the municipal schools would return to opening at the beginning of May, even if some of the teachers had not been vaccinated, in contrast to what had been happening in neighboring cities such as Esteio and São Leopoldo. Days before, the teachers had called for protests against returning to in-person classes during the middle of the pandemic without vaccination.
Loxapine, sold under the brand names Loxitane and Adasuve (inhalation only) among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia and bipolar disorder. It is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic. Loxapine may be metabolized by N-demethylation to amoxapine, a tricyclic antidepressant.
===== Pumping-and-dumping ===== "Pumping-and-dumping" is the concept of expressing breastmilk and discarding it due to a medication or substance "tainting" the breastmilk. It was once believed that drinking alcohol or taking any medications, even medicines like ibuprofen, required pumping-and-dumping. However, this is no longer the case. Pumping-and-dumping, or stopping breastfeeding altogether, is only required in very rare circumstances, such as with radioactive medications or chemotherapy. If a parent is concerned with a possible milk contaminant, they can express and save the breastmilk until they can consult with a lactation specialist or another medical professional trained in breastfeeding medicine.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.